It is not intended for therapeutic application, direct injection, or any use involving humans or animals
Private treatments making unsubstantiated claims should be approached with caution, and patients should verify that practitioners are appropriately qualified and insured
Later research raised more questions
Most of the product licences, or marketing authorities as they are called in the UK, for hydroxocobalamin date from the 1990s when the requirement for evidence was different than it is now
Launching a peptide serum from scratch requires a certain level of formulation expertise, especially because peptides are sensitive ingredients that require stable formulation environments
For established keloids, other treatments remain the primary approach